There’s a New Benefit in Town: Psychedelic Therapy. Are Companies Ready to Embrace It?

BY Lesley Alderman, LCSW | October 16, 2023

Especially since the pandemic, companies have been trying to increase access to quality mental health care for their distressed employees. For good reason: Nearly one in five Americans are currently being treated for depression and three out of four workers report feeling burned out, according to Gallup. At the same time, there’s been rising interest in an unconventional approach to treat mental maladies: psychedelic therapy. Many researchers believe that psychedelics, paired with psychotherapy, have the potential to transform health care.

The prospect that psychedelics could become mainstream has inspired entrepreneurial interest. One company, Enthea, has become the first to offer psychedelic-assisted therapy (PAT) as an employee benefit for U.S. companies. Launched last year with $3.3 million in seed money, led by Tabula Rasa Ventures, Enthea now has seven customers signed on—including Dr. Bronner’sLaunchbox, and Black Swan Yoga—and 50 more in the pipeline, according to Sherry Rais, Enthea’s co-founder and CEO. To be sure, advocates of PAT will face a complicated road ahead, since psychedelics vary widely in their properties and are covered by a crazy quilt of state and federal regulation, but assertions of PAT’s beneficial effects are being supported by a growing field of scientific research.

How Psychedelics Can Help 

It takes time for our brains to change longstanding patterns. Psychedelics, including ketamine, psylocibin (a/k/a magic mushrooms), and MDMA (a/k/a ecstasy) can speed up the process and create profound changes in perspective. How? Taking psychedelics has the potential to change one’s brain for the better. They silent repetitive ruminations, promote neuroplasticity, and can surface new emotions and memories.

When used under the guidance of trained clinicians, research has found that psychedelics may help “patients to achieve meaningful improvements in function, symptomatology, and overall outlook in a relatively short amount of time,” according to a review published in 2022. Here’s how PAT works: the patient takes a measured dose of a psychedelic substance under the supervision of a clinician. A trained therapist prepares the patient for the experience, which can last one to several hours, and helps them make sense of what comes up during and after, a process called integration. “It’s not just as simple as taking a capsule and hoping for the best,” said Paul Hutson, director of the Transdisciplinary Center for Research in Psychoactive Substances at the University of Wisconsin-Madison, in a December 2022 presentation.

By quieting the hum of worries and concerns that plague one’s brain, anxieties may soften. New cell growth and connections help make some of these changes more permanent. Meanwhile, new emotions can be processed and new insights into the past or patterns of behavior can be explored. These developments can lead to feelings of relief and often long-term change.

“I felt like I let go of a lot of anger and resentment towards my parents,” a cancer patient in a psylocibin trial at New York University explained in a paper published in 2017. “I mean, I thought I had already done that, but I really hadn’t, and I kind of saw them more as, like, these flawed human beings who did the best they could,” the patient said.

“Psychedelics are mind manifesters,” Alex Belser, a psychedelic researcher and psychologist at Yale University, told From Day One. “Some aspect of the mind is being manifested that had not been present before. The challenge is to transform altered states into altered traits.”

A Healthcare Entrepreneur’s Journey

For nearly a decade, Enthea co-founder Sherry Rais traveled the globe working on poverty-reduction programs in the developing world. One of her conclusions: You can’t solve poverty without also addressing mental health. And to address mental health, you need effective, low-cost, and accessible treatments. 

She started to look for novel solutions and was “blown away,” she said by the research on psychedelic medicines. But she realized that implementing these treatments in the developing world would be premature, she told From Day One.

Sherry Rais, Enthea’s co-founder and CEO (Company photo)
Sherry Rais, Enthea’s co-founder and CEO (Company photo)

Instead, she and her partners founded Enthea as a public benefit corporation, deriving its name from the term entheogen, which describes substances that can produce changes in consciousness, perception, and mood. Besides offering PAT as a benefit for employers, the company plans to initiate programs for underserved communities, such as formerly incarcerated individuals. Said Rais: “Access and health equity are extremely important to Enthea’s mission.”

Over the next few years, Rais hopes to be working with hundreds of employers, millions of employees and to have increased awareness about and acceptance of psychedelic therapies, which at the moment is rarely covered by insurers.

What’s In It for Employers

Workers are struggling, and they expect their companies to help. A recent workplace wellness study by the Employee Benefit Research Institute (EBRI) found that 79% of employees agree with the statement, “Your employer has a responsibility to make sure employees are mentally healthy and emotionally well.”

According to an EBRI survey, about 61% of employers offer mental health benefits and despite the uncertain economic environment, they are not likely to cut back in benefits of this kind. A healthier workforce, after all, is a more productive workforce—and a less expensive one. Workers who rate their mental health as fair or poor report four times more absences than their colleagues with good or excellent mental well-being, according to a Gallup survey.

Will employers embrace PAT as a new offering? Paul Fronstin, PhD, director of health-benefits research at EBRI, is circumspect: “Most employers don’t want to be first,” he told From Day One. “They will wait on the sidelines to see what others are doing and how it’s working out.” And he added that ultimately, companies want benefits that help their bottom line. If PAT prevents workers from requiring expensive in-patient hospital stays, it could be a win-win for employees and employers. 

Psychedelic Properties Explained

There’s a lot of hype around psychedelics and a lot of time and money being poured into investigating them. These mind-bending drugs, which include ketamine, MDMA (methylenedioxymethamphetamine), psylocibin, and LSD, can help soothe suffering in people with terminal illnesses, veterans struggling with PTSD, individuals with treatment-resistant depression and even those grappling with persistent addiction. However, most are not legal or FDA approved.

Ketamine, an anesthetic that can also alleviate depression, has a leg up on the others: it’s legal and has been used safely in surgical settings for more than 50 years. In 2019, the Food and Drug Administration (FDA) approved a version of ketamine, Spravato (esketamine), for treatment-resistant depression. Many clinics use ketamine off-label to treat a range of a ailments (beyond the approved use of treatment-resistant depression) from mild depression to anxiety. 

Some companies sell ketamine lozenges via email and then monitor patients via telemedicine. The FDA recently issued an alert about the dangers of treating psychiatric disorders with compounded versions of ketamine. 

MDMA, which was developed in 1912 to control bleeding and became celebrated in the 1980s as a “club drug,” may be effective at treating a range of mental health issues, and is gradually gaining traction for therapeutic use. In 2017 the FDA granted Breakthrough Therapy status for MDMA as a potential treatment for PTSD; this status allows clinical trials to be conducted to test MDMA’s safety and efficacy. The following year, the FDA granted the same status to psyilocibin. 

An important study published last month showed that MDMA-assisted therapy was effective at reducing symptoms of PTSD. The drug is on track to be an FDA-approved drug in 2024. If approved, “MDMA-assisted therapy would be the first novel treatment for PTSD in over two decades,” Berra Yazar-Klosinski, the senior author of the study, told the New York Times. “PTSD patients can feel some hope.”

Psychedelics, except ketamine, are illegal on the federal level for recreational use, but states and cities are making their own laws, the pattern followed with the decriminalization of cannabis. In 2020, Oregon approved decriminalizing small amounts of psychedelics and the supervised use of psilocybin in a therapeutic setting. Colorado passed a ballot measure to decriminalize psychedelic mushrooms and to create state-regulated centers where participants can experience the drug under supervision. Several cities in California–Oakland, San Francisco, Santa Cruz, and Berkeley–have decriminalized psylocibin.

Enthea, as this time, offers only ketamine-assisted therapy to its customers. The company has a credentialing process to ensure that the clinics providing the therapy meet high standards of care, Rais said. According to Enthea’s website, a typical ketamine session is one to two hours in length and patients will experience “a sense of detachment from normal reality and self. This may foster increased creativity, purpose, and perspective. It can also enhance feelings of tranquility, insight, inspiration, and gratitude.”

Once MDMA receives regulatory approval for therapeutic use, Enthea will offer that therapy as well. Said Rais: “I really believe people need access to these medicines.” 

Lesley Alderman is a psychotherapist and journalist based in Brooklyn, NY. In her therapy practice, she works with individuals and couples. She writes about mental health topics for the Washington Post and has been an editor at Money and Real Simple magazines and a health columnist for the New York Times.

(Featured photo by Mathia Alvez/iStock by Getty Images)